Milestone Pharmaceuticals Inc. (MIST) has a negative trailing P/E of -2.7, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 5.3 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -37.59%, forward earnings yield 19.05%. PEG 0.04 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 46/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2017 | -44.9 | 0.00 | -10.97 | 0.00 | - |
| 2018 | -15.7 | -0.08 | -6.58 | 0.00 | - |
| 2019 | -4.6 | -0.02 | 2.20 | 0.00 | - |
| 2020 | -3.9 | 0.08 | 1.37 | 0.00 | - |
| 2021 | -6.4 | 0.16 | 2.43 | 18.27 | - |
| 2022 | -2.9 | -0.09 | 2.53 | 33.62 | - |
| 2023 | -1.2 | -0.41 | 4.28 | 71.74 | - |
| 2024 | -3.5 | 0.07 | 11.17 | 0.00 | - |
| 2025 | -2.7 | -0.23 | 4.06 | 109.60 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2017 | $-0.34 | $0.00 | $-8.09M | - |
| 2018 | $-0.98 | $0.00 | $-23.19M | - |
| 2019 | $-3.50 | $0.00 | $-55.23M | - |
| 2020 | $-1.70 | $0.00 | $-49.97M | - |
| 2021 | $-1.02 | $15M | $-42.63M | -284.2% |
| 2022 | $-1.35 | $5M | $-57.13M | -1142.7% |
| 2023 | $-1.39 | $1M | $-59.69M | -5968.5% |
| 2024 | $-0.67 | $0.00 | $-41.52M | - |
| 2025 | $-0.75 | $1.55M | $-63.06M | -4078.8% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.40 | $-0.71 – $-0.04 | $53.56M | $5.02M – $102.09M | 3 |
| 2027 | $-0.86 | $-1.22 – $-0.56 | $29.13M | $25.14M – $33.11M | 3 |
| 2028 | $-0.15 | $-0.25 – $-0.02 | $165.83M | $58.78M – $256.91M | 1 |
| 2029 | $0.39 | $0.06 – $0.66 | $273.53M | $96.95M – $423.76M | 1 |
| 2030 | $0.91 | $0.15 – $1.56 | $363.4M | $128.8M – $562.98M | 1 |
